Pharmaceutical Excipients Market worth $15.99 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the pharmaceutical excipients market to grow from USD 11.95 billion in 2026 to USD 15.99 billion by 2031, a 10.2% CAGR. Asia Pacific is forecast to be the fastest-growing region, while organic chemicals are expected to account for 86.2% of the market in 2025. The report cites rising demand for generics, biologics and specialized formulations, alongside capacity investment and Roquette’s acquisition of IFF Pharma Solutions, announced at an enterprise value of up to USD 2.85 billion.

Analysis

The investable signal is mix shift, not the headline market-growth estimate: formulation complexity and qualification requirements may favor specialty polymers, coatings and high-purity excipients over commodity ingredients. That could support Evonik (EVK), BASF (BAS) and Croda (CRDA), but the disclosed capacity and facility investments establish strategic intent—not incremental revenue, pricing power or returns. Added capacity can also intensify competition before demand is proven.

The report's figures materially conflict: USD 11.95bn in 2026 to USD 15.99bn in 2031 implies roughly 6% annual growth over five years, not the stated 10.2%; its Asia-Pacific CAGR of 6.7% also cannot be the fastest-growing region if the global rate is 10.2%. Treat the forecast as promotional until definitions, periods and underlying model are reconciled. The cited FDA pilot may reduce friction for novel excipients, but does not by itself establish faster adoption or revenue.

Days: limited fundamental signal; avoid trading on the release. Over 1–3 months, monitor segment disclosures, utilization, customer qualification and evidence of pricing/mix. Over 6–18 months, specialty products could gain share, while regional capacity and supplier qualification create switching costs. Main reversal: weak drug-development/manufacturing demand, delayed qualification, or new capacity compressing returns. The contrarian opportunity is to favor demonstrated specialty mix and returns over broad TAM exposure; no company-specific earnings sensitivity is established here.

Key Decisions for Investors

• No immediate trade from this press release. Before assigning value to the market forecast, reconcile the 2026–2031 CAGR and Asia-Pacific growth claims against the report's definitions and source data.
• Watch EVK, BAS and CRDA for disclosed excipient sales or mix, capacity utilization, customer wins and returns on recent investment. Consider a relative long in the supplier showing measurable specialty growth versus diversified chemical exposure only after those indicators confirm demand; avoid sizing from the TAM estimate alone.
• Track IFF separately: the article describes the sale of Pharma Solutions, not growth in IFF's remaining business. Verify transaction completion, proceeds use and any reported continuing-business effects before taking a directional view.
• Falsify the specialty-mix thesis if upcoming results show no improvement in relevant product mix or utilization, if guidance indicates weak formulation demand, or if additional capacity coincides with price/margin pressure.